Interventions to improve HPV vaccine uptake: a systematic review

EB Walling, N Benzoni, J Dornfeld, R Bhandari… - …, 2016 - publications.aap.org
OBJECTIVE: Identification of effective strategies is necessary to optimize uptake of the HPV
vaccine. We systematically reviewed the literature for national and international …

Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis

HB Ferrer, C Trotter, M Hickman, S Audrey - BMC public health, 2014 - Springer
Abstract Background Vaccination against Human Papillomavirus (HPV) is recommended for
adolescent young women prior to sexual debut to reduce cervical cancer related mortality …

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional …

K Kavanagh, KG Pollock, K Cuschieri… - The Lancet infectious …, 2017 - thelancet.com
Summary Background On Sept 1, 2008, Scotland launched routine vaccination for human
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …

[HTML][HTML] Status of HPV vaccine introduction and barriers to country uptake

KE Gallagher, DS LaMontagne, D Watson-Jones - Vaccine, 2018 - Elsevier
During the last 12 years, over 80 countries have introduced national HPV vaccination
programs. The majority of these countries are high or upper-middle income countries. The …

Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and …

TJ Palmer, K Kavanagh, K Cuschieri… - JNCI: Journal of the …, 2024 - academic.oup.com
Background High-risk human papillomavirus causes cervical cancer. Vaccines have been
developed that significantly reduce the incidence of preinvasive and invasive disease. This …

Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study

T Palmer, L Wallace, KG Pollock, K Cuschieri… - bmj, 2019 - bmj.com
Objective To quantify the effect on cervical disease at age 20 years of immunisation with
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …

Present status of human papillomavirus vaccine development and implementation

R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

K Kavanagh, KGJ Pollock, A Potts, J Love… - British journal of …, 2014 - nature.com
Background: In 2008, a national human papillomavirus (HPV) immunisation programme
began in Scotland for 12–13 year old females with a three-year catch-up campaign for those …

Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

KGJ Pollock, K Kavanagh, A Potts, J Love… - British journal of …, 2014 - nature.com
Background: In Scotland, a national HPV immunisation programme began in 2008 for 12-to
13-year olds, with a catch-up campaign from 2008 to 2011 for those under the age of 18. To …

Declining awareness of HPV and HPV vaccine within the general US population

OG Chido-Amajuoyi, I Jackson, R Yu… - Human vaccines & …, 2021 - Taylor & Francis
Programs aimed at boosting human papillomavirus (HPV)-related awareness are
considered one of the most effective strategies for increasing vaccination uptake and …